Bogani G et al. Mirvetuximab soravtansine-gynx: First antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer 2023;[Online ahead of print]. Abstract
Chan JK et al. Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer — An NRG/GOG study. Gynecol Oncol 2023;181:54-9. Abstract
Chan JK et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecol Oncol 2022;167(3):429-35. Abstract
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
Eskander RN et al. Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol 2023;13:1258228. Abstract
González-Martín A et al. Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023;189:112908. Abstract
Graybill W et al. Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 Study. ASCO 2023;Abstract 5589.
Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. ASCO 2023;Abstract LBA5506.
Konstantinopoulos PA et al. EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncol 2022;18(31):3481-92. Abstract
Liu J et al. An open-label phase 2 study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial. SGO 2021;Abstract 10415.
Mirza MR et al. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Cancer 2023;129(12):1846-55. Abstract
Monk BJ et al. Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: Opposing views of the US Food and Drug Administration and European Medicines Agency. Int J Gynecol Cancer 2023;22(6):1008-9. Abstract
Monk BJ et al. Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer 2023;33(6):971-81. Abstract
Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract
Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract
Moore MS et al. Robotic-assisted gynecologic surgery in an older population: A comparison study. J Geriatric Oncol 2023;14(6):101533. Abstract
Nemunaitis J et al. Clonal neoantigen: Emerging “mechanism-based” biomarker of immunotherapy response. Cancers (Basel) 2023;15(23):5616. Abstract
Randall LM et al. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: Results of a phase II study (MOONSTONE/GOG-3032). Gynecol Oncol 2023;178:161-9. Abstract
Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
You B et al. Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study. ASCO 2022;Abstract 5553.